Ann: Botanix Investor Presentation, page-7

As always another professional preso.. some key takeaways I spotted..

"Competitive products with less ideal safety profiles and potentially poorer efficacy, have generated more than US $1bn per annum"

"BTX 1503 is a safe and well tolerated topical acne treatment that potentially addresses all the key causes of acne" (Loved the use of the world potentially) -

"Papulopustular rosacea is a chronic skin disease characterised by redness (inflammation) and acne like break-out

Hints everywherre.. One must ask why the rosacea now? Perhaps the 'acne like break-out' is the key takeaway? Why chase a similiar market otherwise?

Join the dots..

Phase 1B for BTX 1702 will only take 6 weeks also.. then straight on to phase 2 no doubt.

Also great to see some patent explanation.. that's the beauty of having an ex patent attorney I guess..

Not sure what else we can ask from management.

Great work.